Dr. Florin Rader reviews the results of treatment with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study in patients with obstructive hypertrophic cardiomyopathy (HCM).
Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM
Restart
Resume
Transcript
Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
Dr. Florin Rader reviews the results of treatment with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study in patients with obstructive hypertrophic cardiomyopathy (HCM).
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?